Standardizing Opioid Prescriptions to Patients After Ambulatory Oncologic Surgery Reduces Overprescription.
Journal
Joint Commission journal on quality and patient safety
ISSN: 1938-131X
Titre abrégé: Jt Comm J Qual Patient Saf
Pays: Netherlands
ID NLM: 101238023
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
04
10
2019
revised:
17
03
2020
accepted:
15
04
2020
pubmed:
6
6
2020
medline:
29
7
2021
entrez:
6
6
2020
Statut:
ppublish
Résumé
Overprescribing of opioids after surgery contributes to long-term abuse. Evaluating opioid prescription patterns and patient-reported opioid use offers an evidence-based method to identify potential overprescription. This quality improvement initiative aimed to reduce and standardize opioid prescriptions upon discharge from an ambulatory oncologic surgery center and evaluate the effect of this change on patients' subsequent opioid use and reported pain. Between March 2018 and January 2019, consecutive opioid-naïve patients aged ≥ 18 years who underwent robotic or laparoscopic hysterectomy, radical prostatectomy, or partial nephrectomy, or total mastectomy with or without immediate reconstruction were surveyed 7-10 days postoperatively. Data collected in the pre- (n = 551) and post-standardization (n = 480) cohorts included perception of pain relief, opioids prescribed (verified by electronic medical record review) and consumed, and refills received. Pre-standardization, the median opioid prescription at discharge was 20 pills (interquartile range [IQR] 20-28) or 140 oral morphine milligram equivalents (MME) (IQR 100-150). Median opioid consumption was 2 pills (IQR 0-7) or 10 MME (IQR 0-40) among all services. Opioid prescriptions were later standardized to 7, 8, and 10 pills (35, 40, and 75 MME), in the gynecology, urology, and breast services, respectively. The change was not associated with an increase in reported pain. Refill requests increased postintervention across all surgeries from 4.4% to 7.7%, with the largest increase among patients who underwent breast surgery. The number of opioid pills given at discharge to patients undergoing ambulatory or short-stay cancer surgery can safely be reduced.
Sections du résumé
BACKGROUND
Overprescribing of opioids after surgery contributes to long-term abuse. Evaluating opioid prescription patterns and patient-reported opioid use offers an evidence-based method to identify potential overprescription. This quality improvement initiative aimed to reduce and standardize opioid prescriptions upon discharge from an ambulatory oncologic surgery center and evaluate the effect of this change on patients' subsequent opioid use and reported pain.
METHODS
Between March 2018 and January 2019, consecutive opioid-naïve patients aged ≥ 18 years who underwent robotic or laparoscopic hysterectomy, radical prostatectomy, or partial nephrectomy, or total mastectomy with or without immediate reconstruction were surveyed 7-10 days postoperatively. Data collected in the pre- (n = 551) and post-standardization (n = 480) cohorts included perception of pain relief, opioids prescribed (verified by electronic medical record review) and consumed, and refills received.
RESULTS
Pre-standardization, the median opioid prescription at discharge was 20 pills (interquartile range [IQR] 20-28) or 140 oral morphine milligram equivalents (MME) (IQR 100-150). Median opioid consumption was 2 pills (IQR 0-7) or 10 MME (IQR 0-40) among all services. Opioid prescriptions were later standardized to 7, 8, and 10 pills (35, 40, and 75 MME), in the gynecology, urology, and breast services, respectively. The change was not associated with an increase in reported pain. Refill requests increased postintervention across all surgeries from 4.4% to 7.7%, with the largest increase among patients who underwent breast surgery.
CONCLUSION
The number of opioid pills given at discharge to patients undergoing ambulatory or short-stay cancer surgery can safely be reduced.
Identifiants
pubmed: 32499083
pii: S1553-7250(20)30095-7
doi: 10.1016/j.jcjq.2020.04.004
pmc: PMC8290876
mid: NIHMS1719671
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
410-416Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2020. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Conflicts of Interest All authors report no conflicts of interest.
Références
JAMA Surg. 2018 Nov 1;153(11):1012-1019
pubmed: 30027289
J Am Coll Surg. 2019 Jan;228(1):81-88.e1
pubmed: 30359828
Ann Surg. 2018 Mar;267(3):468-472
pubmed: 28267689
PLoS One. 2016 Jan 29;11(1):e0147972
pubmed: 26824844
Mayo Clin Proc Innov Qual Outcomes. 2019 May 27;3(2):183-188
pubmed: 31193969
BMJ. 2014 Feb 11;348:g1251
pubmed: 24519537
Lancet. 2017 Jul 29;390(10093):437-439
pubmed: 28792397
Gynecol Oncol. 2017 Jan;144(1):187-192
pubmed: 27839789
J Pain. 2016 Feb;17(2):131-57
pubmed: 26827847
J Urol. 2020 Jan;203(1):151-158
pubmed: 31464563
J Clin Oncol. 2017 Dec 20;35(36):4042-4049
pubmed: 29048972
J Surg Oncol. 2019 Jun;119(7):909-915
pubmed: 30737785
Urology. 2019 Jan;123:101-107
pubmed: 30149041
JAMA. 2013 Oct 2;310(13):1369-76
pubmed: 24084922
J Am Coll Surg. 2018 Sep;227(3):374-381
pubmed: 30056059
Ann Surg. 2017 Apr;265(4):728-730
pubmed: 27429023
Curr Opin Anaesthesiol. 2010 Dec;23(6):697-703
pubmed: 20847690
Oncologist. 2017 Jan;22(1):115-121
pubmed: 27742907
J Minim Invasive Gynecol. 2018 May - Jun;25(4):684-688
pubmed: 29154933
Clin Colon Rectal Surg. 2013 Sep;26(3):191-6
pubmed: 24436674
JAMA Surg. 2017 Nov 1;152(11):1066-1071
pubmed: 28768328
Plast Reconstr Surg. 2017 Dec;140(6):1081-1090
pubmed: 29176408
Can J Anaesth. 2016 Jan;63(1):31-7
pubmed: 26431852
Eur Urol. 2019 Feb;75(2):215-218
pubmed: 30352714
Anesth Analg. 2010 Apr 1;110(4):1170-9
pubmed: 20142348
Surgery. 2018 Nov;164(5):926-930
pubmed: 30049481
J Surg Oncol. 2019 Sep;120(4):593-602
pubmed: 31297826
J Urol. 2011 Feb;185(2):551-5
pubmed: 21168869
JAMA Netw Open. 2018 Dec 7;1(8):e185452
pubmed: 30646274
Gynecol Oncol. 2019 Oct;155(1):119-125
pubmed: 31405609
Arch Intern Med. 2012 Mar 12;172(5):425-30
pubmed: 22412106
Ann Surg. 2017 Apr;265(4):709-714
pubmed: 27631771
J Endourol. 2020 Jan;34(1):48-53
pubmed: 31595766